Intellia Therapeutics, Inc.
Extracted from this filing and checked against the source text.
Intellia Therapeutics, Inc. shareholders approved Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-09 meeting.
The stockholders of the Company ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.View on SEC.gov
Intellia Therapeutics, Inc. shareholders approved Election of Class I Directors at the 2026-06-09 meeting.
The stockholders of the Company elected each of Muna Bhanji, R.Ph., Brian Goff and Jesse Goodman, M.D., M.P.H., as a class I director, for a three-year term ending at the annual meeting of stockholders to be held in 2029 and until his or her successor has been duly elected and qualified or until his or her earlier resignation or removal.View on SEC.gov
Intellia Therapeutics, Inc. shareholders approved Non-binding advisory vote on compensation of named executive officers at the 2026-06-09 meeting.
The stockholders of the Company approved, on a non-binding advisory basis, the compensation of our named executive officers.View on SEC.gov
1639 shareholder votes filed in the last 30 days. Browse all shareholder votes →
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.